Cardiologists explore advances in lipid management, from statin intolerance to emerging lipid targets like ApoB and non-HDL cholesterol. The series emphasizes the pivotal role of combination therapy—including ezetimibe, PCSK9 inhibitors, and novel agents such as bempedoic acid and inclisiran—in achieving LDL-C goals. Special focus is given to cholesteryl ester transfer protein (CETP) inhibition as a breakthrough strategy, with trials showing potent LDL-C reduction, improved goal attainment, and promising effects on cognition and inflammation. Together, these discussions highlight how CETP inhibitors may redefine future cardiovascular therapy.

Join Drs. Scott Solomon and John McMurray as they examine the new indication for finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in treating patients with heart failure with LVEF ≥40%. Drawing on data from the FINEARTS-HF trial, faculty discuss patient selection, dosing considerations based on renal function, and the additive benefits of combining finerenone with SGLT2 inhibitors. A clinical case illustrates typical comorbidities—atrial fibrillation, hypertension, and diabetes—and how finerenone may address multiple cardiovascular and metabolic risks.

This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

Improving the overall quality of life for patients with heart failure with reduced ejection fraction, or HFrEF, is a key component of their care. But many patients may fail to reach symptom relief or experience improved functional status, even when receiving optimized pharmacologic guideline-directed medical therapy (GDMT). Medical devices like Barostim™ – or baroreflex activation therapy (BAT) – can play an important role in heart failure treatment and positively impact outcomes for these patients.

Can you recognize the symptoms of major depressive disorder? Do you know when to augment and when to switch therapies? Join our experts for these answers and learn about novel treatments on the horizon. Don’t miss this opportunity to enhance your clinical practice and positively impact the lives of your patients.

This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available.

*Episodes 1–3 were posted pre-ESMO on 9/26, and Episodes 4–6 were posted post-ESMO on 11/11.

This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available.

*Episodes 1–3 were posted pre-ESMO on 9/26, and Episodes 4–6 were posted post-ESMO on 11/11.